• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[对乙酰氨基酚在正常、酗酒及肝硬化受试者中的药代动力学与代谢情况]

[Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects].

作者信息

Villeneuve J P, Raymond G, Bruneau J, Colpron L, Pomier-Layrargues G

出版信息

Gastroenterol Clin Biol. 1983 Nov;7(11):898-902.

PMID:6653975
Abstract

It is well known that a chemically reactive metabolite of acetaminophen formed in the liver can cause hepatic necrosis. The amount of cysteine and N-acetylcysteine derivatives excreted in the urine is an index of the amount of reactive metabolite produced. We have examined the pharmacokinetics and the pattern of acetaminophen metabolites in the urine, in 6 healthy controls, in 9 alcoholic subjects without liver disease, and in 11 patients with alcoholic cirrhosis but abstaining from alcohol. In alcoholics, oral clearance of the drug was similar to that of control subjects, but the amount of cysteine and N-acetylcysteine conjugates excreted in urine was significantly increased. In cirrhotics, the clearance of acetaminophen was decreased by 50 p. 100, but the pattern of urinary metabolites was unchanged. These results support previous anecdotal reports of increased acetaminophen hepatotoxicity in alcoholic subjects.

摘要

众所周知,对乙酰氨基酚在肝脏中形成的化学反应性代谢产物可导致肝坏死。尿液中排泄的半胱氨酸和N - 乙酰半胱氨酸衍生物的量是所产生的反应性代谢产物量的一个指标。我们已经研究了6名健康对照者、9名无肝脏疾病的酗酒者以及11名戒酒的酒精性肝硬化患者中对乙酰氨基酚的药代动力学和尿液中代谢产物的模式。在酗酒者中,该药物的口服清除率与对照受试者相似,但尿液中排泄的半胱氨酸和N - 乙酰半胱氨酸结合物的量显著增加。在肝硬化患者中,对乙酰氨基酚的清除率降低了50%,但尿液代谢产物的模式没有改变。这些结果支持了先前关于酗酒者中对乙酰氨基酚肝毒性增加的传闻报道。

相似文献

1
[Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects].[对乙酰氨基酚在正常、酗酒及肝硬化受试者中的药代动力学与代谢情况]
Gastroenterol Clin Biol. 1983 Nov;7(11):898-902.
2
[Alcohol-paracetamol syndrome: a case report].[酒精-对乙酰氨基酚综合征:一例报告]
Przegl Lek. 2002;59(4-5):381-3.
3
The influence of disulfiram on acetaminophen metabolism in man.双硫仑对人体对乙酰氨基酚代谢的影响。
Xenobiotica. 1991 Feb;21(2):243-9. doi: 10.3109/00498259109039466.
4
Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity.酗酒者体内谷胱甘肽缺乏:对乙酰氨基酚肝毒性的危险因素。
Gut. 1988 Sep;29(9):1153-7. doi: 10.1136/gut.29.9.1153.
5
Acetaminophen metabolism in recovering alcoholics.恢复期中酗酒者的对乙酰氨基酚代谢
Methods Find Exp Clin Pharmacol. 1990 Sep;12(7):513-5.
6
[Trace elements (zinc, copper, manganese) in alcoholic cirrhosis: effect of chronic alcoholism].酒精性肝硬化中的微量元素(锌、铜、锰):慢性酒精中毒的影响
Gastroenterol Clin Biol. 1985 Oct;9(10):664-9.
7
Effects of N-acetylcysteine on acetaminophen covalent binding and hepatic necrosis in mice.
J Pharmacol Exp Ther. 1985 Mar;232(3):864-72.
8
Hepatic effects of acetaminophen. Enhanced toxicity in alcoholics.对乙酰氨基酚的肝脏效应。在酗酒者中增强的毒性。
J Clin Gastroenterol. 1987 Apr;9(2):180-5. doi: 10.1097/00004836-198704000-00014.
9
The influence of alcoholism and cirrhosis on benzodiazepine receptor function.酗酒和肝硬化对苯二氮䓬受体功能的影响。
Pharmacol Biochem Behav. 1998 Apr;59(4):949-54. doi: 10.1016/s0091-3057(97)00513-3.
10
Effects of alcoholism on acetaminophen pharmacokinetics in man.酗酒对人体对乙酰氨基酚药代动力学的影响。
J Clin Pharmacol. 1984 Apr;24(4):205-8. doi: 10.1002/j.1552-4604.1984.tb01832.x.

引用本文的文献

1
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Adults With Chronic Alcohol Use or Low Glutathione.对慢性饮酒或谷胱甘肽水平低的成年人过量服用缓释和速释制剂后对乙酰氨基酚的药代动力学和肝脏生物标志物进行定量系统毒理学建模。
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1236-1251. doi: 10.1002/psp4.70045. Epub 2025 May 14.
2
Fructose as a novel nutraceutical for acetaminophen (APAP)-induced hepatotoxicity.果糖作为对乙酰氨基酚(APAP)诱导的肝毒性的新型营养保健品。
Metab Target Organ Damage. 2023;3(4). doi: 10.20517/mtod.2023.28. Epub 2023 Oct 29.
3
Opioid use and risks in candidates and recipients of liver transplant.
肝移植候选者及受者中的阿片类药物使用与风险
Liver Transpl. 2025 Feb 1;31(2):231-241. doi: 10.1097/LVT.0000000000000388. Epub 2024 Apr 29.
4
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.《2022年韩国肝脏癌协会-韩国国立癌症中心肝细胞癌管理实践指南》
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.
5
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2022KLCA-NCC 韩国肝细胞癌管理实践指南。
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
6
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
7
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Korean J Radiol. 2019 Jul;20(7):1042-1113. doi: 10.3348/kjr.2019.0140.
8
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Gut Liver. 2019 May 15;13(3):227-299. doi: 10.5009/gnl19024.
9
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.2014年韩国肝癌研究组-韩国国立癌症中心肝细胞癌管理实践指南
Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.
10
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.2014年韩国肝脏研究学会-国立癌症中心肝细胞癌管理韩国实践指南
Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.